Codexis and Molecular Assemblies Announce Results of First Collaboration on a Proprietary High Performing DNA Polymerase to Supercharge Fully Enzymatic DNA Synthesis

Back
  • Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step to overcome the length, purity, and accuracy limitations of the current chemical DNA synthesis method
  • The collaboration between Molecular Assemblies and Codexis leveraged Codexis’s CodeEvolver® technology to develop a high performing enzyme to enable Molecular Assemblies’ Fully Enzymatic Synthesis and Key Customer Program start in late 2022

REDWOOD CITY, Calif. and SAN DIEGO, April 12, 2022 – Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA. Using a highly evolved DNA polymerase, developed by Codexis, to enable its Fully Enzymatic Synthesis™ (or FES™) technology, select companies and institutions will be able to access a Key Customer Program that is slated to begin later this year.

The Fully Enzymatic Synthesis technology developed by Molecular Assemblies employs a template-independent DNA polymerase, terminal deoxynucleotidyl transferase (TdT), which has the ability to synthesize much longer DNA sequences with fewer errors in an aqueous solution. Naturally occurring TdT has many limitations to commercial use. In order to accelerate innovation for the field, Molecular Assemblies and Codexis partnered in 2020 to engineer an enzyme to deliver differentiated and cost-effective solutions for the fully enzymatic synthesis of DNA.

John Nicols, Codexis’ President and CEO, said, “The successful completion of this first collaboration with Molecular Assemblies has resulted in a highly evolved version of TdT polymerase that delivers unparalleled coupling efficiency and speed at elevated temperatures. We believe the ability to exclusively deploy this proprietary enzyme will significantly differentiate Molecular Assemblies’ Fully Enzymatic Synthesis technology from not only other emerging players but also the current industry-standard phosphoramidite chemistry method.”

“Not only did the enzyme performance surpass expectations, but the collaboration with Codexis has also been phenomenal, and we look forward to continuing to advance our relationship,” said Michael J. Kamdar, President and CEO of Molecular Assemblies. “Participants in our upcoming Key Customer Program, which will launch later this year, will be the first to benefit from this highly enhanced TdT polymerase. With our FES technology, we have the ability to generate long, pure, accurate DNA to accelerate innovation in many fields, such as CRISPR gene editing technologies, next generation sequencing, and the assembly of genes for numerous synthetic biology applications.”

Scientists at Molecular Assemblies have developed a Fully Enzymatic Synthesis technology that produces highly pure, sequence-specific DNA on demand. This two-step proprietary process uses aqueous non-toxic reagents, requires minimal post-synthesis processing, and can scale to longer DNA sequences. FES technology was specifically designed by Molecular Assemblies to overcome the limitations of the current decades-old chemical DNA synthesis process, known as the phosphoramidite method. Due to the limitation of current chemistries, genes are routinely assembled using short pieces of DNA. With longer, purer pieces of synthetic DNA, FES technology from Molecular Assemblies is designed to streamline synthetic biology applications and meet significant customer demand for faster turnaround times and reduced error rates.

Starting later this year, Molecular Assemblies will kick off a Key Customer Program to provide select researchers priority access to long, custom oligonucleotides synthesized with its FES technology. This program  is expected to enable researchers to accelerate their research for gene editing including CRISPR technologies, next generation sequencing (NGS), and gene assembly applications. Key Customers will also be able to provide feedback to shape the future of enzymatic DNA synthesis.

At the Built with Biology Conference on Thursday at 2:30 pm PT, William J. Efcavitch, Ph.D., Chief Scientific Officer and cofounder of Molecular Assemblies, and Mathew Miller, Principal Scientist at Codexis, will be speaking in a breakout session, called “Breaking the Barrier to Long, High Purity Synthetic DNA.” They will also be discussing the partnership between Codexis and Molecular Assemblies, co-development of the proprietary TdT enzyme, and how it enables FES technology.

About Molecular Assemblies

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ Fully Enzymatic Synthesis™ (or FES™) technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including prospects for Codexis’ first collaboration with Molecular Assemblies. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers; and potential adverse effects to Codexis’ business if its products or the products of its customers are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022, including under the caption “Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

CONTACTS

Codexis:

Investors: Brendan Strong/Carrie McKim, Argot Partners, Codexis@argotpartners.com, +1 (212) 600-1902

Molecular Assemblies:

Company: Stephen Bates, VP Sales and Marketing, info@molecularassemblies.com 

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1 (858) 344-8091

Molecular Assemblies Announces $25.8 Million Series B Financing to Initiate Key Customer Program for Commercial Access to Fully Enzymatic DNA Synthesis

Back
  • The Fully Enzymatic Synthesis™ (or FES™) technology by Molecular Assemblies is designed to overcome the length, purity, and accuracy limitations of the chemical DNA synthesis method
  • The company is launching a key customer program to accelerate innovation in established industries and unlock new applications for synthetic DNA

SAN DIEGO, March 15, 2022 — Molecular Assemblies, Inc., today announced that it has raised a $25.8 million Series B financing with participation from new investor, Casdin Capital, and all major Series A investors, Agilent Technologies, iSelect Fund, Codexis, LYFE Capital, and Argonautic Ventures. The proceeds of the financing will be used to advance the company’s proprietary enzymatic DNA synthesis technology toward early commercialization and start a key customer program later this year.

“From therapeutics to agriculture and biomaterials, DNA synthesis is a crucial component of many industries, and enzymatic DNA synthesis can overcome the immense bottleneck of the current chemical DNA synthesis method to accelerate innovation,” said Michael Kime, Managing Principal of iSelect Fund. “Molecular Assemblies is a pioneer in the field of enzymatic DNA synthesis, and our additional investment in the company underscores our support for their approach, team, and technology.”

“It’s great to see the continued support and excitement of our investors as we advance our powerful, differentiated, and proprietary Fully Enzymatic Synthesis technology to commercial access and enable the cost-effective production of ever-lengthening strands of DNA,” said Michael J. Kamdar, President and CEO of Molecular Assemblies. “We look forward to initiating our key customer program later this year and have received compelling input and interest from different industry leaders of how the ability to generate long, pure, accurate DNA with our FES technology can accelerate many applications, such as CRISPR, next generation sequencing, and the assembly of genes for numerous synthetic biology applications.”

Scientists at Molecular Assemblies have developed a Fully Enzymatic Synthesis™ (or FES™) technology that produces highly pure, sequence-specific DNA on demand. This two-step proprietary process uses aqueous non-toxic reagents, requires minimal post-synthesis processing, and can scale to longer DNA sequences. FES technology was specifically designed  by Molecular Assemblies to overcome the substantial limitations of the current decades-old chemical DNA synthesis process, known as the phosphoramidite method. With longer, purer pieces of synthetic DNA, FES technology from Molecular Assemblies is designed to streamline synthetic biology applications and meet significant customer demand for faster turnaround times and reduced error rates.

“As a key, long time investor in Molecular Assemblies, we continue to be impressed with the company’s thorough approach to enzymatic DNA synthesis; it has the potential to make a significant difference in the market,” said Darlene Solomon, Ph.D., Senior Vice President and Chief Technology Officer for Agilent Technologies. “From the solid group of investors to the talented and experienced team and the meaningful collaboration with Codexis, I believe Molecular Assemblies has all the right pieces to be successful.”

Due to the limitation of current chemistries, genes are routinely assembled using pieces of synthetic DNA of between 50 and 100 bases in length. The Fully Enzymatic Synthesis technology developed by Molecular Assemblies employs a template-independent DNA polymerase, called terminal deoxynucleotidyl transferase (TdT), which has the ability to synthesize much longer DNA sequences with fewer errors in an aqueous solution. However, naturally occurring TdT has several limitations to commercial use. To accelerate innovation for the field, Molecular Assemblies and Codexis partnered in 2020 to engineer enzymes to deliver differentiated and cost-effective solutions for the fully enzymatic synthesis of DNA.

John Nicols, Codexis’ President and CEO, concluded, “Having just completed one of the most intensive enzyme engineering campaigns in Codexis’ history, the resulting highly evolved version of TdT polymerase, which had over 25% of its amino acid sequence modified, delivers unparalleled coupling efficiency and speed at elevated temperatures. We believe this will significantly differentiate Molecular Assemblies’ Fully Enzymatic Synthesis technology from other emerging players and the current industry standard phosphoramidite method. I look forward to Molecular Assemblies exclusively deploying this proprietary enzyme to unlock the enormous commercial potential of enzymatic DNA synthesis.”

About Molecular Assemblies

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

Contacts

Company: Stephen Bates, VP Sales and Marketing, info@molecularassemblies.com 

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Molecular Assemblies Awarded NIH Phase I SBIR Grant to Develop a Fully Enzymatic DNA Synthesis Process to Propel Synthetic Biology

Back

SAN DIEGO, October 19, 2021 — Molecular Assemblies, Inc., today announced that it has been awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant (Award No. R43HG011679) from the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH). The grant supports Molecular Assemblies’ development of a fully enzymatic synthesis cycle for a complete workflow for DNA synthesis, with commercial potential for implementation as a replacement for chemical DNA manufacturing.

DNA synthesis has revolutionized the field of synthetic biology, leading to new therapeutics, bio-based fuels and chemicals, and materials. However, the current, three-decade-old method for chemically synthesizing DNA is inherently limited to relatively short DNA sequences, requires extensive post-synthesis processing, and uses hazardous chemicals. While enzymatic synthesis holds the potential to create long, highly pure DNA, most approaches still rely on chemical steps, which can degrade the DNA product and ultimately limit the commercial potential.

“Synthetic biology has outpaced chemical DNA synthesis technology with research and applications being limited by cost and length of synthesized DNA,” said J. William Efcavitch, Ph.D., Cofounder and Chief Scientific Officer of Molecular Assemblies. “A fully enzymatic DNA synthesis platform has the potential to deliver long, highly pure DNA to drive innovation in many industries, especially life sciences, DNA-based data storage, and advanced agricultural and industrial products.”

Scientists at Molecular Assemblies have pioneered a two-step enzymatic DNA synthesis process that can deliver highly pure, sequence-specific DNA on demand, without a template, and can scale to longer DNA sequences. This proprietary process uses aqueous, non-toxic reagents and requires minimal post-synthesis purification and processing. This grant will further Molecular Assemblies’ process by developing three key enzymatic steps: 1) proprietary polymerase incorporation of 3′-O-blocked nucleotides, 2) an enzymatic deblocking step to remove the blocking group from the 3′-hydroxyl, and 3) a novel enzymatic clean-up to deplete unreacted material.

“With this recognition and funding from NIH and NHGRI, we believe we can create and commercialize a fully enzymatic DNA synthesis that can overcome the significant limitations of phosphoramidite chemistry and enable the cost-effective production of ever-lengthening strands of DNA,” said Michael J. Kamdar, President and CEO of Molecular Assemblies.

The contents of this press release are solely the responsibility of the author and not necessarily the official views of the NIH.

About Molecular Assemblies

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

Media Contact:

Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

SynBioBeta 2019

San Francisco | October 1-3, 2019

October 1 | 2:30 – 3:15 PM | DNA Data Storage (Main Stage)

Megan Molteni (Wired), Bill Peck (Twist), Karin Stauss (Microsoft), Bill Efcavitch (Molecular Assemblies), Henry Lee (Kern Systems)

October 2 | 2:30 – 3:15 PM | Enzymetic DNA Synthesis (Breakout Room)

Dan Arlow (Ansa Bio), Tom Baiga, Tim Brears, Michael Kamdar (Molecular Assemblies), Thomas Ybert, Jihao Huang, Henry Lee (Kern Systems)

SynBioBeta 2022

Oakland | April 11-14, 2022

Panel: Breaking the Barrier to Long, High Purity Synthetic DNA

Thursday, April 14 at 2:30pm to 3:15 pm PT in Breakout Room 1

Joe Smith

Joe Smith has more than 40 years of business and legal experience. Most recently he was Senior Vice President, Business Development and General Counsel of Cepheid, a leading developer of integrated systems for genetic assessment. Continue reading

Molecular Assemblies Expands Executive Leadership Team

Back

SAN DIEGO, June 16, 2021 — Molecular Assemblies, Inc., today announced that it has expanded the Company’s executive leadership team with the appointment of Stephen R. Bates as Vice President, Sales and Marketing and the promotion of Leigh F. Elkolli, CPA to Vice President, Finance and Human Resources. The expansion occurs as the Company advances its proprietary enzymatic DNA synthesis technology toward early commercialization efforts.

Michael J. Kamdar, President and CEO of Molecular Assemblies, said, “Stephen has extensive experience in commercializing novel products that have had an enormous impact on life science markets. This coupled with Leigh’s strong financial acumen and experience within the life sciences sector will be key as we launch our first products and position the Company for long-term growth.”

“Molecular Assemblies is poised to revolutionize the $9.5 billion field of synthetic biology,” said Mr. Bates. “Unlike other DNA synthesis chemistries, the proprietary enzymatic synthesis chemistry from Molecular Assemblies has the potential to produce high fidelity DNA required for life sciences applications, including generating vaccines, therapeutics, and diagnostics.”

Ms. Elkolli said, “I am excited to take on increased responsibilities as we execute on our vision. I look forward to working with the executive team and to implement business strategies that enhance the Company’s position as a market pioneer adding value for our stakeholders.”

Stephen R. Bates is an accomplished senior level executive, with more than 30 years of experience building and growing companies in life sciences markets. Prior to joining Molecular Assemblies, he held the position of Senior Vice President for Sales, Marketing and Support at Labcyte Inc., acquired by Beckman Coulter, where he was responsible for leading and driving all aspects of commercial operations including direct and indirect sales channels, product marketing, marketing communications, customer service and customer support. Prior to that Mr. Bates was President and General Manager of MMI Genomics, Inc. and Vice President of Celera Genomics’ agriculture division. Stephen started his career at Applied Biosystems, where he was the European Marketing Manager, introducing an array of benchtop DNA synthesizers, DNA sequencers and genetic analyzers. Mr. Bates helped start the company’s Applied Markets groups focused on agriculture, human identification and environmental analysis. These application-driven businesses are now ubiquitous in genetic testing laboratories around the globe.

Leigh F. Elkolli, CPA, joined Molecular Assemblies in 2019 as Senior Director of Finance. She has more than 20 years of experience in corporate finance in the biotechnology and life sciences sectors having served in senior level finance roles of several privately held and publicly traded companies. Most recently, Ms. Elkolli served as Chief Financial Officer of REVA Medical, Inc., an international medical technology company that launched their first product during her tenure. Prior to REVA, she held senior level finance roles with Avidity Biosciences, Inc. and ImpediMed, Ltd. Ms. Elkolli spent seven years with Ernst & Young, LLP in their assurance services practice supporting mainly life sciences, high tech, and medical technology companies through annual audits and quarterly reviews, public offerings, acquisitions, and a corporate spin-off. Ms. Elkolli currently serves on the Board of The Waldorf School of San Diego. She received her B.B.A. in accounting from Western Connecticut State University and is a certified public accountant with the State of California.

About Molecular Assemblies

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The Company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

Media Contact:

Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing to Advance Enzymatic DNA Synthesis toward Initial Commercial Access

Back

SAN DIEGO, April 15, 2021 — Molecular Assemblies, Inc., today announced that it has closed an oversubscribed $24 million Series A financing with significant investment from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments, and Argonautic Ventures. In addition LYFE Capital has joined the syndicate. The proceeds of the financing will be used to advance the company’s proprietary enzymatic DNA synthesis technology toward early commercialization efforts.

“We have made significant progress in advancing our proprietary enzymatic DNA synthesis technology,” said Michael J. Kamdar, President and CEO of Molecular Assemblies. “Over the past year, we’ve entered into a transformative partnership with Codexis and joined a new project with GE Research to enable the production of nucleic acid-based vaccines and therapeutics, anywhere in the world. We are delighted to have closed our Series A and are rapidly advancing our efforts towards early commercial access.”

“Enzymatic DNA synthesis holds the potential to revolutionize many industries, including life sciences, DNA-based data storage, and advanced agricultural and industrial products,” said Sameer Rohatgi, Venture Partner at LYFE Capital.  “With Molecular Assemblies’ proprietary technology and approach, we saw not only their ability to serve a billion-dollar commercial market, but also to be the DNA ‘ink’ in any genomics printer.”

Synthetic DNA is used in a wide range of applications, including life science research, biologic therapeutics and diagnostics, data storage, nanotechnology, and industrial processes for agriculture, plastics, fermentation, and bio-materials, such as leather or spider silk. However, the full potential of synthetic DNA has not been realized due to the cumbersome process of chemical DNA synthesis. The current, three-decade-old method for chemically synthesizing DNA is inherently limited to relatively short DNA sequences, requires extensive post-synthesis processing, and uses hazardous chemicals.

“We have supported Molecular Assemblies over several years and are very with impressed the progress they have made,” said Darlene Solomon, Ph.D., Senior Vice President and Chief Technology Officer for Agilent Technologies. “The cost-effective production of ever-lengthening strands of DNA will fuel even greater opportunities for nucleic acid driven innovation and contribution across numerous industries.”

John Nicols, Codexis’ President and CEO, adds, “Codexis and Molecular Assemblies have delivered substantial enzymatic synthesis improvements already in the short time since the collaboration was established in June of last year. Codexis’ engineered enzyme performance continues to accelerate and is well on its way to reach the milestones required to differentiate versus the industry standard phosphoramidite chemistry method. It’s great to be enabling the enzymatic DNA synthesis revolution together with Molecular Assemblies.”

Scientists at Molecular Assemblies have pioneered a two-step enzymatic DNA synthesis process that can deliver highly-pure, sequence-specific DNA on demand, without a template, and can scale to longer DNA sequences. This proprietary process uses aqueous, non-toxic reagents and requires minimal post-synthesis purification and processing. Enzymatic DNA synthesis can overcome the significant limitations of phosphoramidite chemistry and enable the cost-effective production of ever-lengthening strands of DNA.

About Molecular Assemblies

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego.

Media Contact:

Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Molecular Assemblies to Provide Enzymatic Synthesis Technology to DARPA NOW Project for On-Demand DNA/RNA Vaccine Manufacturing

Back

Enzymatic synthesis to replace cumbersome chemical synthesis technology that requires hazardous chemicals and extensive post-synthesis processing

– Molecular Assemblies to receive up to $6.5 million as part of larger, up to $41 million project

-Rapidly scalable and deployable mobile platform could increase speed at which new medical countermeasure, such as COVID-19 vaccines, could be deployed in response to a pandemic

SAN DIEGO, March 2, 2021 /PRNewswire/ — Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced the company’s participation in a new project with a multidisciplinary team, led by GE Research, to enable the production of DNA- and/or RNA-based vaccines and therapeutics, anywhere in the world in just days. The project is part of a new program from the Defense Advanced Research Projects Agency (DARPA) called NOW (Nucleic Acids On-Demand Worldwide). As part of the project, Molecular Assemblies will receive up to $6.5 million and contribute the company’s proprietary enzymatic DNA synthesis technology, which uses aqueous, non-toxic reagents and is designed to deliver on-demand highly-pure, sequence-specific DNA. 

DARPA’s NOW program, managed by Dr. Amy Jenkins in the Biological Technologies Office, was created to develop a rapid, mobile medical manufacturing platform for producing, formulating, and packaging DNA- and/or RNA-based vaccines and therapeutics for use in stabilization and humanitarian operations and to better prepare deployed field-forward forces against bio-threat attacks and emerging infectious diseases.

“The speed and success of nucleic acid vaccines in combating COVID-19 have been truly amazing, and we have an exceptional opportunity and responsibility to make our medical countermeasures for pandemic response faster and more accessible,” said Michael J. Kamdar, President and CEO of Molecular Assemblies. “Our enzymatic DNA synthesis technology is an exceptional fit for on-demand manufacturing of DNA/RNA vaccines and therapeutics because it is designed to deliver higher purity, uses non-toxic reagents, and minimizes purification and processing.”

The four-decade-old method for chemically synthesizing DNA and RNA is inherently limited to short DNA sequences, requires extensive post-synthesis processing, and uses hazardous chemicals. Scientists at Molecular Assemblies have pioneered a novel, two-step enzymatic DNA synthesis method. This proprietary, template-free process can scale to longer DNA sequences, uses aqueous reagents, and requires minimal post-synthesis purification and processing. Molecular Assemblies’ enzymatic nucleic acid synthesis approach is designed to reliably, affordably, and sustainably produce long, high quality DNA, which could then be converted to RNA, optimized for biomedical applications.

The GE team, comprised of Dr. John Nelson and his colleagues, Wes Griffin, Ph.D., Erik Kvam, Ph.D., and Brian Davis, Ph.D., represents a highly multidisciplinary group with deep expertise in chemistry, molecular biology, cell biology, fluidic handling, engineering, automation, and quality control to simplify the production of DNA therapies. Dr. Nelson said, “Together with our project partners, we bring all of the elements required to design this mobile manufacturing platform.”

GE’s project, called RUN FAST (Rapid Universal Nucleic Acids using Fieldable Automated Synthesis Technology), will leverage the expertise of the GE Research team, led by Dr. Nelson, to build automated systems in the biological production of medicines and therapies with a novel synthetic method for making DNA and RNA to assemble a complete mobile medical manufacturing platform. For more on GE’s project, see their press release here.

About GE Research
GE Research is GE’s innovation powerhouse where research meets reality. We are a world-class team of scientific, engineering, and marketing minds working at the intersection of physics and markets, physical and digital technologies, and across a broad set of industries to deliver world-changing innovations and capabilities for our customers. To learn more, visit our website at https://www.ge.com/research/.

About Molecular Assemblies
Molecular Assemblies, Inc. is a private biotech company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries, including industrial synthetic biology and precision medicine, as well as emerging applications

Media Contact:
Jessica Yingling, Ph.D., Little Dog Communications Inc.jessica@litldog.com, +1.858.344.8091